Abstract: The present invention relates to metallic-surface detection systems for determining target substances including free bilirubin in neonatal serum in the presence of a predominantly high background of bilirubin bound Human Serum Albumin (HSA) or sensing and isolating target nucleotide sequences wherein a fluorescence signal is enhanced by close proximity of the target substances near metallic surfaces.

Abstract: The methods and apparatus disclosed herein concern nanoparticle layers uniformly distributed on a surface or substrate. In certain embodiments of the invention, the nanoparticle layers are of use for Raman spectroscopy. In certain embodiments of the invention, a micelle-metal ion complex is formed and deposited on a surface. The polymer component of the micelle-metal ion complex may be removed resulting in formation of nanoparticles of a uniform size and distribution. The polymers may contain one or more ligands. The number and type of ligands in a micelle will determine the type and amount of metal ion bound to the micelle, in turn determining the metal composition and size of the nanoparticles. The distribution micelle-metal ion complexes on a surface may determine the distribution and periodicity of the nanoparticle layer. In other embodiments, rod or columnar-shaped nanoparticles may be generated. Other embodiments concern the generation of uniform alloy nanoparticles.

Abstract: Methods and devices are provided for detecting the presence of both ozone and carbonyl-containing compounds in air samples. Method and device for detecting the presence of ozone and carbonyl-containing compounds in an air sample, the method comprising: (a) contacting an air sample with an ozone-reactive adsorbent wherein if ozone is present in the air sample, the ozone reacts with the ozone-reactive adsorbent to form an aldehyde product; (b) contacting the air sample from Step (a) further with a carbonyl-reactive adsorbent wherein if a carbonyl-containing compound is present in the air sample, the carbonyl-containing compound reacts with the carbonyl-reactive adsorbent to form a first hydrazone product; (c) eluting with a solvent from the carbonyl-reactive adsorbent into the ozone-reactive adsorbent, wherein any aldehyde product of step (a) forms a second hydrazone product; and (d) analyzing eluate from Step (c) for presence of hydrazone products formed in Step (b) and Step (c).

Abstract: According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as novel synthesis routes for key intermediates used in those processes.

Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.

Abstract: Process for determination of a drug or medicament or their metabolites in a (body) fluid or an extract of (body) tissue or (body) sample comprising the steps: (i) optionally treatment of the fluid or sample extract with at least one enzyme, (ii) contacting at least a first part of the fluid or extract with at least one first solid phase able to adsorb or absorb organic compounds out of the fluid or extract, and/or (iii) contacting at least a second part of the fluid or extract with at least one second phase, able to extract or adsorb organic compounds out of the fluid or extract, and/or (iv) optionally contacting at least a third part of the fluid or extract with a liquid phase able to extract organic compounds out of the fluid or extract, and/or (v) desorbing the compound(s) bound to the first solid phase by applying heat to the solid phase and/or by solvent extraction, optionally followed by evaporating the solvent at least partially, (vi) optionally extracting or desorbing the compound(s) contained in or b

Abstract: A method for measuring a concentration of creatinine includes the steps of: (A) mixing a sample containing creatinine with a creatinine quantitative reagent containing a metal complex of at least one of hexacyanoferrate and hexacyanoruthenate in the absence of picric acid and any enzyme responsive to creatinine, to cause the creatinine to reduce the metal complex; (B) electrochemically or optically measuring the amount of the metal complex reduced in the step (A); and (C) determining the concentration of the creatinine contained in the sample from the amount of the reduced metal complex measured in the step (B).

Abstract: The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers.

Abstract: The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.

Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

Abstract: The present invention provides a novel oral cancer and periodontal disease salivary metabolome for use in the diagnosis or for providing a prognosis for oral cancer and periodontal disease in an individual. The present invention also provides novel methods of diagnosing or providing a prognosis for oral cancer or periodontal disease by detecting metabolites found in the saliva of an individual. Finally, the present invention provides kits for the detection of salivary metabolites useful in the diagnosis or prognosis of oral cancer and periodontal disease in an individual.

Abstract: The present invention is directed to methods of treating pest infestation by inhibiting metabolic processes of the pest such as for example, processes involved in invertebrate remodelling.

Abstract: The invention provides biomolecule binding ligands, collections of biomolecule binding ligands, and their use in the purification of biological mixtures and in the identification of ligands having an affinity for a substance.

Abstract: The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

Abstract: Methods using chemiluminescent label compounds and chemiluminescent labeled conjugates are provided. The compounds comprise an acridan ring bearing an exocyclic ketene dithioacetal group and further contain a labeling substituent which permits attachment to compounds of interest. The novel chemiluminescent compounds and labeled conjugates are convenient to prepare, are highly stable, and generate chemiluminescence rapidly on demand. The compounds and conjugates are useful in assays of an analyte in a sample and in assays employing labeled specific binding pairs.

Abstract: There is provided a method of diagnosing a disease state in a subject. The disease state is caused or effected by pneumococcal infection. The method includes obtaining a biological test sample from the subject. The biological sample includes at least one metabolite selected from the group consisting of citrate, trigonelline, acetylcarnitine, acetone, myo-inositol, 3-hydroxybutyrate, glucose and carnitine. A respective concentration of each one of the at least one metabolite is compared with a predetermined concentration value associated with a corresponding one of the at least one metabolite. The predetermined concentration value is indicative of the disease state. For example, the biological sample includes any one of citrate, trigonelline, acetylcamitine, acetone, myoinositol, 3-hydroxybutyrate, glucose and carnitine. As a further example, the biological samples include any combination of citrate, trigonelline, acetylcamitine, acetone, myo-inositol, 3-hydroxybutyrate, glucose and carnitine.

Abstract: The present invention provides a single self-contained device for collecting, extracting, on-site testing, and transferring for forensic confirmatory analysis, a wide variety of substances including, but not limited to, drugs of abuse, explosives, weapons of mass destruction, food toxins and industrial wastes. Samples can be obtained from a surface by swabbing a suspect area or the testing of solid materials (pills, capsules, powders), air samples and biological and non-biological fluids by placing the substance in the device. The device includes a swab, a retention well including a wash, and analysis technologies that can be, for example, a lateral flow testing system. The swab is rinsed with a wash prior to testing thereby not compromising the chemistry of the detection technologies and allowing for a wide variety of applications under a number of field conditions. Also, the device is a single self-contained unit instead of having a separate reagent droppers or sprays, making it compact and easy to use.

Abstract: A process for determining ionic liquid catalyst deactivation including (a) collecting at least one sample of an ionic liquid catalyst; (b) hydrolyzing the at least one sample to provide at least one hydrolyzed sample; (c) titrating the at least one hydrolyzed sample with a basic reagent to determine a volume of the basic reagent necessary to neutralize a Lewis acid species of the ionic liquid catalyst; and (d) calculating the acid content of the at least one sample from the volume of basic reagent determined in step (c) is described. Processes incorporating such a process for determining ionic liquid catalyst deactivation are also described. These processes are an alkylation process, a process for controlling ionic liquid catalyst activity in a reaction producing by-product conjunct polymers, and a continuous process for maintaining the acid content of an ionic liquid catalyst at a target acid content in a reaction producing by-product conjunct polymers.

Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.

Abstract: A compound represented by the formula (I) wherein R1 and R2 represent amino groups that substitute at adjacent positions on the benzene ring, wherein one of the amino groups may have one alkyl group; R3 and R4 represent hydrogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, R9 and R8 independently represent a C1-6 alkyl group, R6 and R9 represent a carboxy-substituted C1-6 alkyl group, an alkoxycarbonyl-substituted C1-6 alkyl group, a sulfo-substituted C1-6 alkyl group, or an alkyl sulfonate-substituted C1-6 alkyl group, and R7 and R10 represent a C1-6 alkyl group, an aryl group, a C1-6 alkoxycarbonyl group, a vinyl group, a thienyl group, or a pyrrolyl group, and an agent for measurement of nitrogen monoxide containing the compound. Said compound can give a fluorescent substance that is free from change in fluorescence intensity in a wide pH range.

Abstract: The present invention provides a phenothiazine-derivative color-measuring method that can detect a phenothiazine-derivative color even at a wavelength longer than the wavelength that exhibits maximum absorption.

Abstract: The present invention relates to a kit for analysing at least one target molecule comprising at least a first molecularly imprinted polymer and a second molecularly imprinted polymer which are chemically identical or different, capable of interacting with the target molecule(s), and at least one marker, wherein said marker is either a competitive marker or marker capable of (i) of interacting with all or part of the recognition sites for the target molecule(s) of the second molecularly imprinted polymer and (ii) of being displaced from said recognition site(s) by the target molecule(s) when said molecularly imprinted polymer is placed in the presence of said target molecule(s), or an intrinsic marker or a constitutive unit of the second molecularly imprinted polymer, capable (i?) of interacting with all or part of the target molecule(s) when the latter interact(s) with all or part of its recognition sites for said target molecule(s) and (ii?) of consequently emitting a detectable signal.

Abstract: This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1-R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Abstract: The present invention provides sensors and methods for determination of an analyte. The analytes may be determined by monitoring, for example, a change in an optical signal of an emissive material upon exposure to an analyte. In some embodiments, the analyte and the emissive material may interact via a chemical reaction, or other chemical, biochemical or biological interaction (e.g., recognition), to form a new emissive species. In some cases, the present invention may be used for the detection of analytes such as explosives (e.g., RDX, PETN). Methods of the present invention may be advantageous in that the high sensitivity of luminescence (e.g., fluorescence) spectroscopy can allow for the reliable detection of small changes in luminescence intensity.

Abstract: The present invention relates to a reagent for determining the absolute configuration of a chiral compound containing as an active ingredient a metalloporphyrin dimer, wherein the metalloporphyrin dimer has an alkaline-earth metal ion as a central metal and has a carbon chain-crosslinked structure in which at least one of the two porphyrin rings has a substituent bulkier than methyl at least one of the second carbon atoms from a carbon atom bonded to the crosslinking carbon chain along the outer periphery of the porphyrin ring and a method for determining the absolute configuration of an asymmetric carbon atom of the chiral compound using the reagent.

Abstract: The present invention relates to a method of imaging structures and features using plasmonic emissions from metallic surfaces caused by chemiluminescence based chemical and biological reactions wherein imaging of the reactions is enhanced by the use of microwave energy and further enhanced by using metallic geometric structures for spatially and temporally controlling the biological and chemical reactions.

Abstract: The present invention provides various biomarkers of Alzheimer's Disease (AD). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of AD, methods of determining predisposition to AD, methods of monitoring progression/regression of AD, methods of assessing efficacy of compositions for treating AD, methods of screening compositions for activity in modulating biomarkers of AD, methods of treating AD, as well as other methods based on biomarkers of AD.

Abstract: Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of transporters for neurotransmitters, and or neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems. The methods may also include determining a urinary neurotransmitter phase response to a change in dosing of supplemental amino acid precursors of the serotonin and catecholamine neurotransmitters to optimally treat neurotransmitter transporters, neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems.

Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.

Abstract: The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.

Abstract: The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid-templated chemistry, for example, by generating fluorescent polymethine dyes.

Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.

Abstract: The present disclosure provides the asymmetric cyanine fluorescent dyes of formula I in which X, n, R1, R2, R3, R4, R5 and Y? are as defined in the specification. The present disclosure also provides conjugates of the fluorescent dyes, methods for preparation thereof, compositions comprising the fluorescent dyes, and methods for staining biological samples using the fluorescent dyes and compositions thereof.

Abstract: The present invention relates to fluorescent dyes based on acridine derivatives and use of such dyes, for example, in biochemical and/or cell based assays. A preferred feature of some of the dyes described is their long fluorescence lifetimes and their use to label biological molecules.

Abstract: The methods and apparatus disclosed herein concern nanoparticle layers uniformly distributed on a surface or substrate. In certain embodiments of the invention, the nanoparticle layers are of use for Raman spectroscopy. In certain embodiments of the invention, a micelle-metal ion complex is formed and deposited on a surface. The polymer component of the micelle-metal ion complex may be removed resulting in formation of nanoparticles of a uniform size and distribution. The polymers may contain one or more ligands. The number and type of ligands in a micelle will determine the type and amount of metal ion bound to the micelle, in turn determining the metal composition and size of the nanoparticles. The distribution micelle-metal ion complexes on a surface may determine the distribution and periodicity of the nanoparticle layer. In other embodiments, rod or columnar-shaped nanoparticles may be generated. Other embodiments concern the generation of uniform alloy nanoparticles.

Abstract: Ultrasensitive detection of a chemical substance (analyte) by mass spectrometry is achieved by employing a molecular tag that yields an intense parent ion and then an intense daughter ion in a multi-stage mass spectrometer.

Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.

Abstract: The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.

Abstract: The present invention provides a method and apparatus for analyzing compounds with amino group(s) contained in biological organisms. In this method, a compound with amino group(s) is derivatized and then the derivative of the compound with amino group(s) is eluted by liquid chromatography using a stepwise elution means on a concentration gradient. Subsequently, the derivative of the compound with amino group(s) eluted from the liquid chromatography is detected by mass spectrometry.

Abstract: The use of compounds of the general formula (I) as markers for liquids, methods for detecting markers in liquids, methods for identifying liquids and selected compounds of the general formula (I).

Abstract: Provided are methods of detecting the presence or amount of the active form of vitamin B6, pyridoxal 5?-phosphate, in a body fluid sample using tandem mass spectrometry coupled with liquid chromatography.

Abstract: The invention relates to uses and methods relating to grass and endophyte combinations to repel avian species from the grass and endophyte combination. In particular, methods are described to select grass and endophyte combinations in order to enhance or maximise the repellent effect. Preferred endophyte and grass combinations are described which are based on the selection methods and include AR4, AR5, AR8 and AR94 (Deposit Nos. V07/029054, V07/029055, V071029056, V07/029057) in Lolium cultivars as well as AR601, AR602, AR603, and AR604 (Deposit Nos. V07/029058, V07/029059, V07/029060, V07/029061) in Festuca cultivars.

Abstract: Polyfunctional reagents are disclosed that are capable of reversibly binding to target substances, for example nucleic acid, proteins, polypeptides, cells, cell components, microorganisms or viruses, for use in purifying or otherwise manipulating them. The reagents comprise a tagging group for manipulating and/or detecting the target substance when bound to the polyfunctional reagent. The polyfunctional reagents work by binding the target substance at a first pH and then releasing it at a second pH, usually higher than the first. Examples of tagging groups include tagging group members of a specific binding pair which is capable of binding to a specific binding partner and/or a label.

Abstract: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.

Abstract: The present invention relates to methods and kits for detecting an analyte in a test sample using acridinium-9-carboxylate aryl esters.

Abstract: A process for qualitatively or quantitatively detecting a fuel additive component which is part of an analyte comprising a fuel and/or further fuel additive components, by contacting the analyte with an indicator and determining the change, caused by the interaction between fuel additive component and indicator, in the color properties of the indicator in the analyte.

Abstract: The invention relates to methods of manipulating immobilised carbohydrates by derivatisation. Depending on the nature of the derivatisation, the carbohydrate may thereby be more easily detected and/or identified or handled. In particular, the invention relates to methods of preparing a reactive sugar comprising the steps of: i) providing a sample comprising a reducing sugar; ii) providing a solid support covalently attached to a linker comprising a capture group comprising an —NH2 group, wherein said linker optionally is attached to said solid support via a spacer; iii) reacting said reducing sugar with said —NH2 group, thereby obtaining an immobilised sugar; iv) reacting free —NH2 groups with a capping agent, wherein the capping agent comprises a reactive group capable of reacting with an —NH2 group; and v) reducing C?N bonds with a reducing agent, thereby obtaining an reactive sugar of the structure SugarCHn—NH— linked to a solid support via a linker and optionally a spacer, wherein n is 1 or 2.

Abstract: The present invention is directed to the synthesis of molecules guided b connector polynucleotides (CPNs capable of hybridizing to complementary connector polynucleotides (CCPNs) harbouring at least one functional entity comprising at least one reactive group. At least one of said CCPNs capable of hybridize to at least two CPNs. Each CPN will “call” for one or more CCPNs capable of hybridization to the CPN. Following the formation of a supramolecular hybridization complex comprising a plurality of CPNs and a plurality of CCPNs, the reaction of functional entity reactive groups result I the formation of a molecule comprising covalently linked functional entities. The formation of the molecule involves the transfer of functional entities from one or more “donor CCPNs” to at least on “acceptor CCPN” with which the transferred functional entities were not associated prior to the transfer.

Abstract: The present invention relates to compositions and methods for the detection and characterization of interfering RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs) and other short nucleic acid molecules. More particularly, the present invention relates to improved methods for the detection and quantitation of interfering RNA expression. The present invention further provides for the detection of variants and types of miRNAs and siRNAs.

Abstract: Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.